Results 1 to 10 of about 5,010 (170)

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]

open access: yesBMC Cardiovascular Disorders
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi   +4 more
doaj   +3 more sources

Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data [PDF]

open access: yesFrontiers in Medicine
BackgroundAcute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach.
Peng Zhang   +5 more
doaj   +3 more sources

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont   +18 more
doaj   +3 more sources

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

open access: yesCase Reports in Critical Care, 2021
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd   +5 more
doaj   +2 more sources

Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

open access: yesThe Egyptian Heart Journal, 2023
Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian   +5 more
doaj   +2 more sources

A woman with eptifibatide (integrilin)‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review

open access: yesClinical Case Reports
Eptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition.
Morteza Safi   +4 more
doaj   +2 more sources

Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke

open access: yesNeurology International
Objectives: The optimal treatment strategy for ischemic stroke in patients presenting with tandem occlusions of the internal carotid artery remains controversial.
Paweł Latacz   +5 more
doaj   +2 more sources

Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]

open access: yesFrontiers in Neurology
BackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik   +8 more
doaj   +2 more sources

Adaptive Antithrombotic Strategy for Tandem Occlusion Stroke: Escalating Therapy After Thrombectomy and Stenting [PDF]

open access: yesDiagnostics
Background/Objectives: There is no consensus on standardized treatment algorithms for patients with acute ischemic stroke due to anterior circulation tandem occlusions.
Gregory Howaldt   +11 more
doaj   +2 more sources

Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia

open access: yesCase Reports in Cardiology, 2020
Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj   +2 more sources

Home - About - Disclaimer - Privacy